Follow
Federico Pulido
Federico Pulido
Unidad VIH. Hospital Universitario 12 de Octubre, imas12. UCM. Madrid. SPAIN
Verified email at ucm.es
Title
Cited by
Cited by
Year
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ...
The Lancet 381 (9868), 735-743, 2013
6462013
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1133-1144, 2008
5722008
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
3922019
Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV …
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1145-1155, 2008
2592008
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
JR Arribas, A Horban, J Gerstoft, G Fätkenheuer, M Nelson, N Clumeck, ...
Aids 24 (2), 223-230, 2010
2292010
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical …
JR Arribas, F Pulido, R Delgado, A Lorenzo, P Miralles, A Arranz, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (3), 280-287, 2005
2142005
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
HJ Stellbrink, J Reynes, A Lazzarin, E Voronin, F Pulido, F Felizarta, ...
Aids 27 (11), 1771-1778, 2013
2132013
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority …
JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ...
The lancet HIV 5 (5), e211-e220, 2018
2072018
Sustained Virological response to interferon plus Ribavirin reduces non–liver-related mortality in patients Coinfected with HIV and hepatitis C virus
J Berenguer, E Rodríguez, P Miralles, MA Von Wichmann, ...
Clinical infectious diseases 55 (5), 728-736, 2012
1962012
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
F Pulido, JR Arribas, R Delgado, E Cabrero, J González-García, ...
Aids 22 (2), F1-F9, 2008
1942008
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse …
JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ...
The Lancet Infectious Diseases 15 (7), 785-792, 2015
1932015
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
D Podzamczer, E Ferrer, P Sanchez, JM Gatell, M Crespo, C Fisac, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 44 (2), 139-147, 2007
1812007
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study
J Reynes, R Trinh, F Pulido, R Soto-Malave, J Gathe, R Qaqish, M Tian, ...
AIDS research and human retroviruses 29 (2), 256-265, 2013
1742013
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
SMART Study Group*
Annals of internal medicine 149 (5), 289-299, 2008
1672008
Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B
F Laguna, R López-Vélez, F Pulido, A Salas, J Torre-Cisneros, E Torres, ...
Aids 13 (9), 1063-1069, 1999
1571999
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ...
HIV medicine 21 (10), 617-624, 2020
1532020
Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency …
FJ San-Andrés, R Rubio, J Castilla, F Pulido, G Palao, I de Pedro, ...
Clinical infectious diseases 36 (9), 1177-1185, 2003
1472003
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
JR Arribas, R Delgado, A Arranz, R Muñoz, J Portilla, J Pasquau, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (2), 147-152, 2009
1452009
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis
S Mathis, B Khanlari, F Pulido, M Schechter, E Negredo, M Nelson, ...
PloS one 6 (7), e22003, 2011
1392011
Genetic barrier to resistance for dolutegravir.
JM Llibre, F Pulido, F García, M Garcia Deltoro, JL Blanco, R Delgado
AIDS reviews 17 (1), 2015
1302015
The system can't perform the operation now. Try again later.
Articles 1–20